Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda links with Envoy for schizophrenia drug research

This article was originally published in Scrip

Executive Summary

In line with the investment strategy of corporate venture capitalist Takeda Research Investment, which looks at its portfolio companies mainly with a strategic eye, Takeda has entered into an alliance with the private US firm Envoy Therapeutics for the discovery of novel drugs against schizophrenia. , Takeda Research Investment, was an investor in the firm's $8 million series A financing around a year ago.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC010442

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel